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Abstract
Introduction Since urgency is key to the overactive bladder
syndrome, we have reviewed the mechanisms underlying
how bladder filling and urgency are sensed, what causes
urgency and how this relates to medical therapy.
Materials and methods Review of published literature.
Results As urgency can only be assessed in cognitively
intact humans, mechanistic studies of urgency often rely on
proxy or surrogate parameters, such as detrusor overac-
tivity, but these may not necessarily be reliable. There is an
increasing evidence base to suggest that the sensation of
‘urgency’ differs from the normal physiological urge to
void upon bladder filling. While the relative roles of
alterations in afferent processes, central nervous process-
ing, efferent mechanisms and in intrinsic bladder smooth
muscle function remain unclear, and not necessarily
mutually exclusive, several lines of evidence support an
important role for the latter.
Conclusions A better understanding of urgency and its
causes may help to develop more effective treatments for
voiding dysfunction.
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Introduction
Urgency is the key symptom of the overactive bladder
syndrome (OAB) and is defined as ‘the complaint of a
sudden compelling desire to pass urine, which is difficult to
defer’ [1]. A better understanding of the genesis of urgency
and its relationship to other aspects of bladder function is
required to unravel the pathophysiology of OAB and to
develop more effective treatments. An extended version of
the thoughts discussed in this manuscript has been pub-
lished elsewhere [2].
Implications of the use of surrogate parameters
for urgency
The definition of urgency as a desire implies that it can
only be measured in cognitively intact human beings. As a
sensation it can be affected by neurological disorders and
may, therefore, be perceived differently in patients with
neurological lesions. Patient-activated keypad devices [3]
or an ‘urgeometer’ [4] have been proposed as tools to
capture the sensation of urgency in an objective fashion,
but until now they have not been widely used. By contrast,
mechanistic studies on urgency have employed the use of
isolated tissues and experimental animals. As neither
allows assessing a desire, they rely on surrogate markers
such as non-voiding detrusor contractions (NVDCs). Sev-
eral studies have explored the relationship between
urgency and detrusor overactivity (DO). Only about half of
all patients with DO experience urgency [5], whereas
among patients with urgency 44–69% exhibit DO during
pressure-flow studies [6–9]. The correlation of urgency
with DO is higher in males than in females, and in
incontinent compared with continent patients. Possibly
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urgency in the absence of DO is not a separate entity, but
rather part of a spectrum of bladder dysfunction [10].
Finally, abnormal filling sensations can be reported during
fake cystometry [11]. Despite these limitations, NVDCs
remain the most frequently used surrogate parameter to
study mechanisms related to urgency in experimental ani-
mals. Other studies have linked specific mechanisms to the
frequency of detrusor contractions or the number of
incontinence episodes, rather than the occurrence of
urgency. However, not all detrusor contractions are well
captured by standard pressure-flow studies.
Two other factors are pivotal to the understanding of
urgency. Firstly, as urgency is always a pathological sen-
sation, it does not necessarily involve the same mecha-
nisms as those occurring in response to physiological
bladder filling. This limits the extrapolation from findings
in animals or healthy individuals to those with urgency.
Secondly, the ease with which the term urgency is used in
English belies the lack of clarity relating to this distinction
from normality in most other languages. The implications
of all of these issues need to be considered in the inter-
pretation of the subsequently presented data.
Differential sensing of bladder filling and urgency
Physiological filling signals from the bladder are conveyed
to the spinal cord by the pelvic, hypogastric and pudendal
nerves. They comprise thin, but myelinated, Ad-fibres and
even thinner and non-myelinated C-fibres, the latter exhib-
iting slower conductance [12]. The Ad-fibre endings are
located in the detrusor smooth muscle layer and are the most
sensitive nerve endings in the bladder; accordingly, they are
referred to as ‘tension receptors’ and are considered to be
the primary mediators of the physiological sensation of
bladder fullness. On the other hand, the nerve endings of the
C-fibres are found in the urothelium and lamina propria
[13]. The C-fibres are thought to be only activated by
distension that is greater than that required to activate
Ad-fibres and are considered to be less sensitive to con-
traction than to bladder distension. Factors which are con-
sidered to be important in pathology including high
osmolality, high ambient KCl concentration or inflamma-
tion can activate a subgroup of C-fibres. From these data it
can be concluded that C-fibres may primarily be involved in
pathological situations and apparently are less important in
the sensation of physiological bladder filling (except close
to functional bladder capacity); these properties makes them
a better candidate to be involved in the sensation of urgency.
The non-neuronal release of neurotransmitters may also
have a direct stimulatory effect on C-fibres [14, 15]. As they
originate largely from the urothelium [16], the urothelium
may play a specific role in generating urgency.
Several lines of evidence support the concept that
urgency is a pathological sensation which is sensed by
mechanisms which are at least partly distinct from those
involved in sensing bladder filling. For example, some
investigators have explored urgency by determining where
the sensation is felt. In one study patients with painful
bladder syndrome (PBS), OAB, stress urinary incontinence
(SUI) and asymptomatic controls were asked to indicate
the location of their urinary urge/urgency/discomfort on a
body map [17]. Controls and SUI patients localised the
urge to void to the suprapubic region only, whereas more
than half of patients with PBS and a minority of those with
OAB pointed to both suprapubic and vulval/urethral loca-
tions as the source of their urinary urgency/discomfort.
Functional position emission tomography studies have
identified areas within the brain which are activated during
storage and voiding, and these areas are underperfused in
patients with DO [18]. Similar studies have identified that
different areas of the cortex may be active during the per-
ception of the physiological sensation of urge as compared to
urgency [19] and there may be significant differences
between those with ‘good’ as compared to ‘bad’ bladder
control [20]. Some drugs such as opioid receptor agonists,
gabapentin or GABA receptor ligands [21] and also mus-
carinic antagonists with good penetration into the brain such
as oxybutynin [22] may exert beneficial effects on urgency
by interfering with these central processing mechanisms.
What causes non-voiding detrusor contractions
and urgency?
Non-voiding detrusor contractions could result from mul-
tiple causes. These include alterations at the level of the
sensory signals originating in the afferent bladder nerves
(‘sensory urgency’). Equally possible are alterations at the
level of the efferent nerve signals to the detrusor (‘motor
urgency’). Finally, an intrinsic malfunction of the smooth
muscle is also possible (myogenic theory). Of note, these
three possibilities are not necessarily mutually exclusive.
The currently available evidence is insufficient to fully
support one of these theories to the exclusion of any of the
others and indeed it is likely that a different admixture of
pathophysiology is present in different patients. In the
following we will largely focus on the myogenic theory as
this has been investigated in more detail than the other
options and is also supported by circumstantial evidence
from pressure-flow studies [23, 24].
Detrusor smooth muscle contractions can occur spon-
taneously or be evoked by paracrine factors and/or neuro-
transmitters. Physiological voiding appears largely driven
by neurotransmitter-induced detrusor contractions. Human
physiological bladder contractions are evoked by the
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neurotransmitter acetylcholine acting on muscarinic
receptors, largely the M3 receptor [25]. Their coupling to
contraction involves voltage-operated Ca?? channels and
rho kinase [26]. Paracrine mediators of detrusor contraction
include non-neuronal acetylcholine [14] and ATP [27], the
latter acting via ligand-gated ion channels. The relative
contribution of non-neuronal stimuli, is physiologically
low in humans as compared with other species [28] but can
increase under pathological conditions [27, 29]. Alterations
of cellular Ca?? handling [30] and of rho kinase [31] may
occur in disease and can contribute to alterations of muscle
contractility by neuronal and paracrine agents. Spontane-
ous contractions play a smaller role in humans than in
rodents, and it is not fully clear whether they are involved
in the physiological resting tone of the bladder and/or DO,
and/or are an epiphenomenon of in vitro conditions [32].
Micromotions may be an in vivo correlate of spontaneous
contraction [33] and are more frequent in patients with
sensory urgency [34].
Some pathologies leading to bladder dysfunction
including DO and urgency may be associated with struc-
tural alterations of the bladder which can persist even after
the causative insult is removed. For example, mural
changes occur in the bladder wall associated with both
ageing and bladder outlet obstruction (BOO), which
include loss of detrusor muscle volume, decreased neuronal
density, increased intramuscular fibrosis and increased
excitability of detrusor muscle [35]. Moreover, BOO can
be associated with repeated episodes of prolonged detrusor
ischemia [36]. Some of these alterations as well as DO and
urgency can persist after removal of obstruction both in
animals [37] and patients [38].
How do drugs affect non-voiding detrusor contractions
and urgency?
The current medical treatment of OAB largely rests on the
use of muscarinic receptor antagonists [39, 40]. While the
best way to assess urgency in OAB patients is still under
debate [41, 42], several studies, largely based on counting
urgency episodes, have demonstrated reductions of
urgency using several muscarinic receptor antagonists
including darifenacin [43, 44], fesoterodine [45–47], pro-
piverine [48], solifenacin [48–52], tolterodine [46, 50, 53,
54] and trospium [55]. For some drugs beneficial effects on
urgency have also been demonstrated using other means of
assessment including several rating scales [44, 55–61].
Interestingly, several studies indicate that muscarinic
receptor antagonist will reduce urgency episodes also in
continent patients [62], indicating that they may genuinely
have an action on urgency itself and not only produce a
response that is secondary to reducing the number of
incontinence episodes. However, it should not be ignored
that such drugs did not significantly affect urgency in all
studies [57, 63, 64]. Taken together these data demonstrate
that muscarinic receptor antagonists as a class reduce the
number of urgency episodes as well as urgency severity in
OAB patients irrespective of the presence of incontinence
and without major effects on physiological voiding.
Potential novel treatment of urgency, DO and/or OAB
such as b3-adrenoceptor agonists [65], vanilloids [66],
botulinum toxin [67] as well as agents acting on the central
nervous system [68], apparently make use of all of the
above-mentioned mechanisms but their specific effects on
urgency largely remain to be established, particularly in
direct comparison with muscarinic receptor antagonists.
Conclusions
Urgency is a pathological sensation which differs at least
partly from the physiological urge to void upon bladder
filling. Mechanisms involved in urgency are not necessarily
the same as those involved in DO or in other OAB
symptoms such as frequency, nocturia and urgency
incontinence. Specifically, uncertainty concerning the
validity of DO as a surrogate marker of urgency is a
stumbling block for further research in this area. While
muscarinic receptor antagonists have some efficacy against
urgency, a better understanding of the underlying patho-
physiology is likely to help the development of more
effective treatments for this bothersome symptom.
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